Development of COVID-19 Neutralizing Antibody (NAb) Detection Kits Using the S1 RBD Protein of SARS-CoV-2
The COVID-19 virus is a β-genus virus that causes infection by mediating the angiotensin convertible enzyme 2 (ACE2) receptor, which is distributed in large numbers in the human respiratory tract. The disease requires effective post-management of antibody production by complete healers and vaccin...
Main Authors: | Dong Ok Choi, Kang Moon Lee |
---|---|
Format: | Article |
Language: | English |
Published: |
The Korean Society for Clinical Laboratory Science
2021-09-01
|
Series: | Korean Journal of Clinical Laboratory Science |
Subjects: |
Similar Items
-
Quantitative SARS-CoV-2 Spike Antibody Response in COVID-19 Patients Using Three Fully Automated Immunoassays and a Surrogate Virus Neutralization Test
by: Yoonjoo Kim, et al.
Published: (2021-08-01) -
A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients binds to the ACE2-RBD interface and is tolerant to most known RBD mutations
by: Federico Bertoglio, et al.
Published: (2021-07-01) -
Potent neutralizing RBD‐specific antibody cocktail against SARS‐CoV‐2 and its mutant
by: Lina Jia, et al.
Published: (2021-09-01) -
Development of the test kit for detection of SARS-CoV-2 antibodies in sera of susceptible animals
by: M. A. Volkova, et al.
Published: (2021-07-01) -
Estimating the Neutralizing Effect and Titer Correlation of Semi-Quantitative Anti-SARS-CoV-2 Antibody Immunoassays
by: Baek, J.Y, et al.
Published: (2022)